Institution
Charlie Norwood VA Medical Center
Healthcare•Augusta, Georgia, United States•
About: Charlie Norwood VA Medical Center is a healthcare organization based out in Augusta, Georgia, United States. It is known for research contribution in the topics: Autophagy & Kidney. The organization has 349 authors who have published 490 publications receiving 16360 citations. The organization is also known as: Augusta VA Medical Center.
Topics: Autophagy, Kidney, Acute kidney injury, Cancer, Prostate cancer
Papers
More filters
••
TL;DR: Five novel ceramide analogs are developed that act at a sublethal dose to enhance the efficacy of tumor-specific CTLs, and these ceramide Analogs hold great promise for further development as adjunct agents in CTL-based colon cancer immunotherapy.
Abstract: FasL-mediated cytotoxicity is one of the mechanisms that CTLs use to kill tumor cells. However, human colon carcinoma often deregulates the Fas signaling pathway to evade host cancer immune surveillance. We aimed at testing the hypothesis that novel ceramide analogs effectively modulate Fas function to sensitize colon carcinoma cells to FasL-induced apoptosis. We used rational design and synthesized twenty ceramide analogs as Fas function modulators. Five ceramide analogs, IG4, IG7, IG14, IG17, and IG19, exhibit low toxicity and potent activity in sensitization of human colon carcinoma cells to FasL-induced apoptosis. Functional deficiency of Fas limits both FasL and ceramide analogs in the induction of apoptosis. Ceramide enhances FasL-induced activation of the MAPK, NF-κB, and caspase 8 despite induction of potent tumor cell death. Finally, a sublethal dose of several ceramide analogs significantly increased CTL-mediated and FasL-induced apoptosis of colon carcinoma cells. We have therefore developed five novel ceramide analogs that act at a sublethal dose to enhance the efficacy of tumor-specific CTLs, and these ceramide analogs hold great promise for further development as adjunct agents in CTL-based colon cancer immunotherapy.
19 citations
••
TL;DR: The findings indicate that CD8+CD20+ T subset functions in host cancer immunosurveillance and tumor microenvironment suppresses this T subset through a PD-L1-dependent mechanism.
19 citations
•
01 Nov 2014-Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
TL;DR: C-ECT and continuation pharmacotherapy may be more effective than either alone for preventing relapse, however, more definitive randomized clinical trials are needed.
Abstract: Background One-third of patients who suffer from depression are resistant to conventional treatments. An acute course of electroconvulsive therapy (ECT) can lead to remission of depressive symptoms in a substantial portion of the treatment-resistant patients. However, prevention of relapse with depressive symptoms after the index course of ECT can be challenging. We review pertinent studies on the topic and analyze the best strategies to avoid relapse and recurrence of depressive symptoms. Methods We performed a systematic literature review of PubMed through April 2014 for clinical trials published in English to determine if continuation ECT (C-ECT), continuation medication, continuation psychotherapy, or combinations of these are the best strategy to avoid relapse and recurrence of depressive symptoms after an acute course of ECT. Clinical trials comparing ≥2 of the above strategies were included in the review. Results Although there are few rigorous randomized clinical trials in this area, most studies suggest that combined C-ECT and continuation pharmacotherapy are the most effective strategy in relapse prevention. Conclusions C-ECT and continuation pharmacotherapy may be more effective than either alone for preventing relapse. However, more definitive randomized clinical trials are needed.
18 citations
••
TL;DR: DEGs and hub genes identified in this study may deepen the understanding of molecular mechanisms underlying the progression of DN, and provide candidate targets for diagnosis and treatment of DN.
Abstract: Diabetic nephropathy (DN) is a major cause of end-stage renal disease. Although intense efforts have been made to elucidate the pathogenesis, the molecular mechanisms of DN remain to be clarified. To identify the candidate genes in the progression of DN, microarray datasets GSE30122, GSE30528, and GSE47183 were downloaded from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) were identified, and function enrichment analyses were performed. The protein-protein interaction network was constructed and the module analysis was performed using the Search Tool for the Retrieval of Interacting Genes and Cytoscape. A total of 61 DEGs were identified. The enriched functions and pathways of the DEGs included glomerulus development, extracellular exosome, collagen binding, and the PI3K-Akt signaling pathway. Fifteen hub genes were identified and biological process analysis revealed that these genes were mainly enriched in acute inflammatory response, inflammatory response, and blood vessel development. Correlation analysis between unexplored hub genes and clinical features of DN suggested that COL6A3, MS4A6A,PLCE1, TNNC1, TNNI1, TNN2, and VSIG4 may involve in the progression of DN. In conclusion, DEGs and hub genes identified in this study may deepen our understanding of molecular mechanisms underlying the progression of DN, and provide candidate targets for diagnosis and treatment of DN.
18 citations
••
TL;DR: Evidence is provided for vacuolar protein sorting 35 (VPS35), a major component of retromer, in regulating PTH1R trafficking, turning off PTH signaling, and promoting its catabolic function, which may underlie PTH-induced catabolic response and adequate bone remodeling.
18 citations
Authors
Showing all 353 results
Name | H-index | Papers | Citations |
---|---|---|---|
Zheng Dong | 70 | 283 | 24123 |
Lin Mei | 69 | 245 | 15903 |
Wen Cheng Xiong | 64 | 194 | 12171 |
Ruth B. Caldwell | 60 | 214 | 12314 |
Darrell W. Brann | 60 | 188 | 11066 |
Steven S. Coughlin | 56 | 303 | 12401 |
Martha K. Terris | 55 | 375 | 12346 |
Susan C. Fagan | 53 | 179 | 10135 |
Adviye Ergul | 48 | 188 | 7678 |
Kebin Liu | 46 | 128 | 7271 |
Maribeth H. Johnson | 45 | 125 | 5189 |
Azza B. El-Remessy | 44 | 123 | 5746 |
Yutao Liu | 43 | 152 | 5657 |
William D. Hill | 41 | 101 | 9870 |
Yuqing Huo | 41 | 114 | 9815 |